SecBot SecBot
SECBOTREPLAY Home › Report › PTGX

PTGX · CEO Dinesh Patel and Director Bryan Giraudo sold a combined $11.7M in…

Protagonist Therapeutics, Inc · CLUSTER filed May 7, 2026 at 20:00 ET

At the news

NEUTRALIMPACT 5/10

CLUSTER filed May 7, 2026 at 20:00 ET

CEO Dinesh Patel and Director Bryan Giraudo sold a combined $11.7M in open-market shares within a week of PTGX reporting a massive Q1 2026 earnings beat (revenue $56.4M vs. $16.3M consensus, EPS $0.05 vs. -$0.65 consensus). The sales follow the FDA approval of ICOTYDE and a $200M rusfertide opt-out payment, but the CEO's $7.5M sale at ~$100/share, near all-time highs, raises questions about insider conviction at current valuation. At $11.7M total open-market sales, this represents ~0.17% of PTGX's $6.7B market cap, which is modest but notable given the CEO's participation and the post-earnings timing.

  • CEO Dinesh Patel sold 75,000 shares at $100.12 for $7.51M on May 12, 2026
  • Director Bryan Giraudo sold 36,000 shares at $100.14 for $3.61M on May 7, 2026
  • Total open-market sales: $11.71M (0.17% of $6.7B market cap)
  • Sales occurred 2-7 days after Q1 2026 earnings beat (revenue $56.4M vs. $16.3M consensus)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access